Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when AVLN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsAvalyn Pharma restructures governance for IPO, creates dual-class stock with 200M non-voting shares
Filed May 1, 2026 · Period ending May 1, 2026 · ~1 min read
Key Changes
-
high
Company authorized 700M common shares split into 500M voting and 200M non-voting shares, creating a Class A common stock capital structure (full multi-class details, if any, are in the charter exhibit / prospectus — not disclosed in this filing body) that may concentrate voting control with insiders or early investors.
Item 5.03 verify on EDGAR → -
high
Board granted authority to issue up to 10M shares of undesignated preferred stock in future series without shareholder approval, potentially diluting common stockholders.
Item 5.03 verify on EDGAR → -
medium
New bylaws require advance notice for stockholder proposals and director nominations, making it harder for retail investors to participate in governance without planning ahead.
Item 5.03 verify on EDGAR → -
medium
All prior series of preferred stock eliminated as part of the corporate restructuring in connection with the initial public offering.
Item 5.03 verify on EDGAR →
Summary
Avalyn Pharma restructured its corporate governance immediately before its IPO, implementing changes typical for newly public biotech companies but with significant implications for shareholder rights. The company created a Class A common stock capital structure (full multi-class details, if any, are in the charter exhibit / prospectus — not disclosed in this filing body) with 200 million non-voting common shares alongside 500 million voting shares, a setup that often allows founders and early investors to maintain control even as their economic ownership dilutes. The board also gained authority to issue up to 10 million preferred shares in the future without asking shareholders, creating potential for dilution.
Retail investors should understand that the Class A common stock capital structure (full multi-class details, if any, are in the charter exhibit / prospectus — not disclosed in this filing body) may limit their influence over company decisions, even as they bear economic risk. The new advance-notice requirements for stockholder proposals mean investors need to plan months ahead to participate in annual meetings. Watch the company's proxy filings to see how voting power is actually distributed among insiders versus public shareholders, and whether the board uses its preferred stock authorization.
Section-by-Section Diff
Event · Item 5.03 — Amendments to Articles of Incorporation or Bylaws
Avalyn Pharma amended its certificate of incorporation and bylaws in connection with its IPO, authorizing new share classes and governance procedures.
Added in current filing · verify on EDGAR →
The Restated Certificate amends and restates the Company’s existing amended and restated certificate of incorporation, as amended, in its entirety to, among other things: (i) authorize 700,000,000 shares of common stock, including 500,000,000 shares of voting common stock and 200,000,000 shares of non-voting common stock; (ii) eliminate all references to the previously-existing series of preferred stock; and (iii) authorize 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Board in one or more series.
The company filed an amended and restated certificate of incorporation effective immediately prior to its IPO. The amendment authorizes 700 million shares of common stock split between voting and non-voting classes, eliminates prior preferred stock series, and creates 10 million shares of new undesignated preferred stock that the board can issue an undisclosed amount in series. This Class A common stock capital structure (full multi-class details, if any, are in the charter exhibit / prospectus — not disclosed in this filing body) with non-voting shares may concentrate voting control with certain shareholders.
Added in current filing · verify on EDGAR →
The Amended and Restated Bylaws amend and restate the Company’s bylaws in their entirety to, among other things: (i) establish procedures for the Company’s stockholders to take formal actions at meetings of stockholders; (ii) establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our Board; (iii) establish procedures relating to the nomination of directors; and (iv) conform to the amended provisions of the Restated Certificate.
The company adopted amended and restated bylaws effective upon the IPO. The new bylaws establish formal procedures for stockholder meetings, require advance notice for stockholder proposals and director nominations, and align with the restated certificate of incorporation. These governance changes are typical for newly public companies and may make it more difficult for stockholders to bring proposals or nominate directors without advance planning.
Event · Item 9.01 — Financial Statements and Exhibits
Avalyn Pharma filed amended and restated certificate of incorporation and bylaws with no material business impact disclosed.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
3.1 Amended and Restated Certificate of Incorporation of Avalyn Pharma Inc. 3.2 Amended and Restated Bylaws of Avalyn Pharma Inc.
The company filed amended and restated versions of its certificate of incorporation and bylaws. The 8-K provides no detail about what changed in these governing documents or why they were amended.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify